D
9.78
-0.24 (-2.40%)
| Penutupan Terdahulu | 10.02 |
| Buka | 10.02 |
| Jumlah Dagangan | 260,359 |
| Purata Dagangan (3B) | 889,310 |
| Modal Pasaran | 345,368,160 |
| Harga / Pendapatan (P/E TTM) | 326.00 |
| Harga / Pendapatan (P/E Ke hadapan) | 14.31 |
| Harga / Jualan (P/S) | 4.61 |
| Harga / Buku (P/B) | 2.97 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | -26.38% |
| Margin Operasi (TTM) | 3.24% |
| EPS Cair (TTM) | -0.450 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 530.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.27% |
| Nisbah Semasa (MRQ) | 15.95 |
| Aliran Tunai Operasi (OCF TTM) | -6.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -7.11 M |
| Pulangan Atas Aset (ROA TTM) | -1.51% |
| Pulangan Atas Ekuiti (ROE TTM) | -28.13% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Delcath Systems, Inc. | Menurun | Menaik |
AISkor Stockmoo
1.9
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.88 |
|
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 2.73% |
| % Dimiliki oleh Institusi | 45.84% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Rosalind Advisors, Inc. | 30 Sep 2025 | 3,300,389 |
| Propel Bio Management, Llc | 30 Sep 2025 | 438,509 |
| Exoduspoint Capital Management, Lp | 30 Sep 2025 | 379,583 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 30.00 (HC Wainwright & Co., 206.75%) | Beli |
| Median | 22.00 (124.95%) | |
| Rendah | 18.00 (Stephens & Co., 84.05%) | Beli |
| Purata | 23.00 (135.17%) | |
| Jumlah | 4 Beli | |
| Harga Purata @ Panggilan | 10.14 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Stephens & Co. | 05 Nov 2025 | 18.00 (84.05%) | Beli | 8.68 |
| BTIG | 04 Nov 2025 | 23.00 (135.17%) | Beli | 9.08 |
| Canaccord Genuity | 21 Oct 2025 | 21.00 (114.72%) | Beli | 11.39 |
| HC Wainwright & Co. | 20 Oct 2025 | 30.00 (206.75%) | Beli | 11.42 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |